Dendreon Corp (DNDN.O)

DNDN.O on Nasdaq

2.67USD
11:16am EDT
Price Change (% chg)

$-0.02 (-0.74%)
Prev Close
$2.69
Open
$2.69
Day's High
$2.73
Day's Low
$2.66
Volume
614,272
Avg. Vol
3,435,132
52-wk High
$5.38
52-wk Low
$2.23

DNDN.O

Chart for DNDN.O

About

Dendreon Corporation (Dendreon) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that may significantly improve cancer treatment options for patients. The Company's product portfolio includes active cellular immunotherapies and a small molecule product candidate that could be... (more)

Overall

Beta: 2.58
Market Cap (Mil.): $427.64
Shares Outstanding (Mil.): 158.98
Dividend: --
Yield (%): --

Financials

  DNDN.O Industry Sector
P/E (TTM): -- 25.47 33.14
EPS (TTM): -1.95 -- --
ROI: -62.63 -2.90 18.95
ROE: -- -12.19 19.71
Search Stocks

Dendreon shares jump on news of prostate drug's European launch

- Biotechnology company Dendreon Corp said it would start selling its prostate cancer vaccine Provenge in Europe, sending its shares up nearly 15 percent in premarket trading.

03 Mar 2014

Dendreon shares jump on news of prostate drug's European launch

March 3 - Biotechnology company Dendreon Corp said it would start selling its prostate cancer vaccine Provenge in Europe, sending its shares up nearly 15 percent in premarket trading.

03 Mar 2014

Analyst who cast doubt on Provenge vaccine settles with SEC

- A former hedge-fund analyst who argued that Dendreon Corp's therapeutic vaccine for prostate cancer may hasten the death of patients has reached a settlement with U.S. securities regulators over failure to disclose her financial interests in the company.

04 Dec 2013

UPDATE 1-Analyst who cast doubt on Provenge vaccine settles with SEC

Dec 3 - A former hedge-fund analyst who argued that Dendreon Corp's therapeutic vaccine for prostate cancer may hasten the death of patients has reached a settlement with U.S. securities regulators over failure to disclose her financial interests in the company.

04 Dec 2013

Analyst who cast doubt on Provenge vaccine settles with SEC

- A former hedge-fund analyst who argued that Dendreon Corp's therapeutic vaccine for prostate cancer may hasten the death of patients has reached a settlement with U.S. securities regulators over failure to disclose her financial interests in the company.

03 Dec 2013

Dendreon to cut more jobs as cancer vaccine sales drop again

- Biotechnology company Dendreon Corp said it would reduce annual costs by $125 million and cut about 150 jobs in a new round of restructuring, as it struggles to boost sales of its flagship cancer vaccine.

12 Nov 2013

UPDATE 1-Dendreon to cut more jobs as cancer vaccine sales drop again

Nov 12 - Biotechnology company Dendreon Corp said it would reduce annual costs by $125 million and cut about 150 jobs in a new round of restructuring, as it struggles to boost sales of its flagship cancer vaccine.

12 Nov 2013

Dendreon to restructure after drop in cancer drug sales

Nov 12 - Biotechnology company Dendreon Corp said it would restructure to cut costs after reporting another quarter of weak sales of its prostate cancer vaccine, Provenge.

12 Nov 2013

Market Chatter- Corporate finance press digest

Oct 28 - The following corporate finance-related stories were reported by media:

28 Oct 2013

Drug maker Dendreon seeking a buyer: report

- Drug maker Dendreon Corp is looking for a suitor after sales for its lead product, prostate cancer drug Provenge, were weaker than expected, according to a Bloomberg report.

25 Oct 2013

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Pechala's Reports
$25.00
Provider: Stock Traders Daily
$20.00
Provider: ValuEngine, Inc.
$25.00
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks